Dyadic International reported second quarter 2026 revenue of approximately $961,000, essentially flat compared to $967,000 a year earlier, while its net loss widened to $2.1 million from $1.8 million. The company highlighted progress across its life sciences, food and nutrition, and bioindustrial segments, including initial product shipments to IBT Bioservices, pilot sales of recombinant transferrin and growth factors for cultivated meat, and commercial sales of non-animal chymosin by partner Enzymes. Dyadic also disclosed substantial doubt about its ability to continue as a going concern under accounting standard ASC 205-3, citing the need for additional capital, though it noted compliance with convertible note covenants and a maturity date of December 31, 2027. Management said it is evaluating financing alternatives including non-dilutive and strategic sources such as licensing, milestones, and partnerships.
Dyadic International IncNet loss widened and substantial doubt about going concern due to need for additional capital.
